Second-generation IL13Rα2-targeted, 4-1BB co-stimulatory CAR T cells underwent clinical trial [82] whereby CAR T cells were introduced in r/r IL13Rα2+ malignant glioma patients through either intratumoral, intraventricular or dual intratumoral/intraventricular routes. The gene discussed is IL13RA2; the disease is malignant glioma.